Pfizer: Pfizer's RSV vaccine Abrysvo receives European approval to help protect adults aged 1859 against RSV lower respiratory tract disease
Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, the company's bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to
Read full article »
Pfizer is a New York-based pharmaceutical company that develops and commercializes medicines and vaccines for the healthcare industry.
Read more